– 3834 . 48. Chacon JI Mollefo M Munoz E . Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients . Blood 2002 ; 100 : 1648 – 1654 . 49. Troussard X Valenci F Duchayne E
Search Results
Marginal Zone Lymphoma
Omid S. Shaye and Alexandra M. Levine
Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment
Presented by: Stephen D. Smith
Marginal zone lymphoma (MZL) is a heterogeneous group of diseases, but they share common features in terms of etiology and even clinical presentation. Given favorable rates of long-term survival, sequencing and therapy selection play an important
Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma
Aby Z. Philip
Splenic marginal zone lymphoma (SMZL) is a rare low-grade B-cell lymphoma considered a distinct entity in the WHO classification. 1 SMZL accounts for approximately 0.6% of all non-Hodgkin's lymphomas (NHLs), according to the SEER registries, and
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas
Presented by: Ann S. LaCasce and Ariela Noy
durable remission, making this an appealing option for young patients.” According to Dr. LaCasce, providers must consider a variety of patient and disease factors when applying these results to individual patients. R/R Marginal Zone Lymphoma MZL
Gastric MALT Lymphoma Treated With Primary Radiotherapy in the Setting of Autoimmune Disease
Chelsea C. Pinnix, Valerie Reed, and Bouthaina Dabaja
Marginal zone lymphoma (MZL) describes 3 indolent B-cell non-Hodgkin's lymphomas (NHL): splenic MZL, nodal MZL, and extranodal MZL (of mucosa-associated lymphoid tissue [MALT]). Although all 3 share a common cell of origin, the marginal zone B
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin’s Lymphoma
Scott F. Huntington, Jessica R. Hoag, Rong Wang, Amer M. Zeidan, Smith Giri, Steven D. Gore, Xiaomei Ma, Cary P. Gross, and Amy J. Davidoff
, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s lymphoma; MZL, marginal zone lymphoma. Construction of Variables Exposure and Outcome The Healthcare Common Procedure Coding System (HCPCS) code J9310 was used to identify receipt of rituximab from Medicare
Non-Hodgkin's Lymphoma Clinical Practice Guidelines
Memorial Sloan-Kettering Cancer Center
Non-Hodgkin's lymphomas (NHLs) may be classified on the basis of morphology, natural history, and immunophenotypic and molecular characteristics. These guidelines were developed for more common NHL histologic types, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, and for less common entities with unique natural histories and therapies, such as marginal zone lymphoma, mantle cell lymphoma, and highly aggressive lymphoma subtypes, including Burkitt's, and lymphoblastic lymphomas and AIDS-related B-cell lymphomas. Certain components of the diagnosis and therapy of the various NHLs are similar. In all cases, an accurate pathologic diagnosis must first be made.
For the most recent version of the guidelines, please visit NCCN.org
Oncology Research Program
and Marginal Zone Lymphoma Principal Investigator: Stephen D. Smith, MD Conditions: Marginal zone lymphoma, recurrent marginal zone lymphoma, recurrent Waldenström's macroglobulinemia, refractory marginal zone lymphoma, refractory Waldenström
Ten Years of Progress in the Treatment of Non-Hodgkin’s Lymphoma
Julie M. Vose
/small lymphocytic lymphoma or the t(11;18) in gastric marginal zone lymphoma. Various prognostic factor indices have been developed over this time, including the Follicular Lymphoma International Prognostic Index (FLIPI) and the Mantle Cell Prognostic Factor Index
NCCN News
’s New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer NCCN has published new Guidelines for Patients: Marginal Zone Lymphoma . A cancer of the lymphatic system, marginal zone